Report Store | Pharma intelligence
  • My Account
    • 0Shopping Cart
  • $0.00
  • Disease analysis
    • Anemias
    • Bacterial infections
    • Bleeding disorders
    • Brain Cancer
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Cerebrovascular diseases
    • Dermatology
    • Diabetes and diabetic complications
    • Gastroenterology
    • Gastrointestinal cancer
    • Head and Neck Cancer
    • Hypertension
    • Immunology and Inflammation
    • Infectious Diseases
    • Ischemic heart disease
    • Leukemia
    • Lung Cancer
    • Lymphoma
    • Oncology overview
    • Market Spotlight
    • Mens Health
    • Neurology
    • Oncology
    • Ophthalmology
    • Other Hematological Cancers
    • Other metabolic diseases
    • Other Solid Cancers
    • Pain
    • Psychiatry
    • Respiratory
    • Rheumatology
    • Skin cancer
    • Thrombosis
    • Urological cancer
    • Vaccines
    • Viral infections
    • Women’s Health
  • Strategy analysis
    • Bleeding disorders
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Commercial Strategy
    • Dealmaking and R&D
    • Head and Neck Cancer
    • Hot Topics
    • Infectious Diseases
    • KOL Insight
    • Leukemia
    • Lung Cancer
    • Manufacturing
    • Market Access
    • Neurology
    • Oncology
    • Outsourcing
    • Pricing & Reimbursement
    • R&D
    • Regulatory & Therapeutic Area
    • Trends
    • Urological cancer
  • Company analysis
    • Big Pharma
    • Emerging Pharma
    • Hot Topics
    • Japan Pharma
    • M&A Analysis
    • Mid Pharma
  • Drug analysis
    • A
    • B-C
    • D-F
    • G-L
    • M-O
    • P-R
    • S-T
    • U-Z
  • MedTech analysis
    • Allergy
    • Autoimmune / Immunology
    • Cardiovascular
    • Dermatology
    • Endocrine
    • ENT / Dental
    • Gastroenterology
    • Hearing
    • Hematology
    • Infectious Diseases
    • Metabolic
    • Neurology
    • Obstetrics / Gynecology
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Osteoporosis
    • Psychiatry
    • Renal
    • Respiratory
    • Rheumatology
    • Urology
  • Opinion & analysis
    • Business Development
    • Business Management
    • Clinical Trials
    • Digital Health
    • Cybersecurity
    • Compliance & Risk
    • Digital patient management
    • Digital policy & regulation
    • Finance & Pricing
    • Healthcare Innovation
    • ICT and Health
    • Leadership
    • Legislation Regulation & Policy
    • Market Access
    • Market Intelligence
    • Medical
    • Pharmaceutical Device
    • Pharmaceutical Research
    • Strategy & Innovation
    • Tech companies & Data
    • Tech & Pharma
  • Blogs
  • Search
  • Menu
You are here: Home > Opinion & analysis

Opinion & analysis


loader
  • Sort by Price
    • Default
    • Custom
    • Name
    • Price
    • Date
    • Popularity (sales)
    • Average rating
    • Relevance
    • Random
    • Product ID
  • Click to order products ascending
  • Display 15 Products per page
    • 15 Products per page
    • 30 Products per page
    • 45 Products per page

  • Trump’s Drug Pricing ‘Dream Team’ And Prospects For Change

    $131.00

    The US Department of Health and Human Services is hoping for stability in its ranks in order to move its drug pricing reform policy forward, according to HHS Deputy Secretary Eric Hargan. Find out more about anticipated personnel adjustments to the HHS in this Pink Sheet article.

    November 24, 2018
    Find out more

  • CAR-T Label Update Could Address Medicare Coverage Challenges, FDA’s Gottlieb Suggests

    $131.00

    Lifesaving chimeric antigen receptor T-cell (CAR-T) therapies could soon move to outpatient settings, easing the financial burden currently felt by providers, according to US FDA Commissioner Scott Gottlieb, who said a label change to allow for outpatient treatment under Medicare Part B is in the works.

    November 13, 2018
    Find out more

  • Keeping Up With “The Energizer Bunny”: US FDA Commissioner Gottlieb As A Boss

    $131.00

    Both direct reports and external stakeholders weighed in on their thoughts about the leadership of Scott Gottlieb, Commissioner of the US FDA. All signs point to a desire for continuity at the agency following the US mid-term elections in the fall of 2018.

    November 25, 2018
    Find out more

  • Infographic – 2018 Pharma Pipeline Snapshot

    $131.00

    How does the 2018 pipeline compare to 2017’s? In Vivo’s 2018 pipeline infographic examines pipelines by therapeutic area, company and phase. Find out which therapeutic areas are growing, which are shrinking, and which pharma companies have the most robust portfolios.

    May 28, 2018
    Find out more

  • Top 20 Pharma Ranks: As Some Move Up, Others Fall Down

    $131.00

    Although the ranking of Scrip’s top 100 pharma companies remained largely the same as the previous year, there were some surprising moves up – and down – in rank for major players within pharma. Find out who in the top 20 moved, and in what direction, in this essential resource from In Vivo.

    December 13, 2018
    Find out more

  • Cell And Gene Therapy Logistics Requires Early Planning

    $131.00

    Traditionally, the subject of logistics has not been considered until late in the development process for cell and gene therapy. Industry experts at the October 2018 Cell and Gene Meeting on the Mesa in San Diego suggest that considering logistics early in the planning stages for cell and gene therapy is a critically important move.

    December 7, 2018
    Find out more

  • Swiss Regulatory Change Takes Over 500 OTCs Out Of Pharmacy

    $131.00

    Swissmedic, Switzerland’s medicines authority, recently completed a full review of Switzerland’s classification system for medicines, deeming 500 OTCs previously available only in pharmacies now suitable for marketing in drugstores, as well. Read more about this sweeping change and how it is affecting hundreds of OTC medicines in Switzerland.

    December 13, 2018
    Find out more

  • FDA Asks Whether Supplement Industry Has Outgrown Regulatory Framework

    $131.00

    A working group appointed by US FDA Commissioner Scott Gottlieb convened to study the FDA’s capacity to handle the supplement sector and the potential need for Congress to legislate improvements to the agency’s oversight powers in the supplement space.

    December 12, 2018
    Find out more

  • Probiotic Safety Latest Target Of Supplement Regulation Critic Cohen

    $131.00

    Probiotic labeling came under fire in a recent opinion piece published in JAMA Internal Medicine, which called for more detailed and extensive labeling for probiotic supplements, as well as improved good manufacturing practices (GMP) as they pertain to the production of products containing live microorganisms.

    December 5, 2018
    Find out more

  • Gilead Lures Roche Pharma CEO O’Day As CEO; Genentech’s CEO Will Replace Him

    $131.00

    A leadership shakeup at Roche Pharmaceuticals resembles a game of musical chairs, as Roche’s CEO steps down to join Gilead as chairman and CEO, while the lead at Roche-owned Genentech moves over to fill the top position at Roche.

    December 10, 2018
    Find out more

  • Analysts Weigh Up Benefits Of Big Bayer Restructuring

    $131.00

    The recent shakeup at Bayer AG took some observers by surprise, but was heralded by most as a much-needed measure to maintain the German giant’s viability. Find out how this restructuring will play out, and what top analysts make of the move to streamline the organization.

    November 30, 2018
    Find out more

  • Suns Sets In Hawaii On Sunscreens Containing Octinoxate, Oxybenzone

    $131.00

    Hawaii’s ban on the sale of sunscreens containing octinoxate and oxybenzone is expected to go into effect in 2021. It’s intended to protect marine ecosystems–in particular, coral. Opponents of the law included the Consumer Healthcare Product Association and the Hawaii Medical Association. Find out how manufacturers will adjust, and gain insights into the U.S. FDA’s perspective on regulating certain sunscreen ingredients.

    May 2, 2018
    Find out more

  • Estee Lauder Is Revising Claims, Retesting Products After Internal Breakdown

    $131.00

    Estée Lauder’s CEO revealed that “a small group of employees” was responsible for intentionally altering test results behind product claims. The shocking disclosure was mitigated by the fact that the problem was discovered internally. Nevertheless, stock tumbled following the announcement–but has largely recovered. Find out how the disclosure may affect Lauder moving forward, and learn how analysts reacted

    May 16, 2018
    Find out more

  • Let’s Make A Deal: Sanofi Regeneron Extend A Hand On Praluent, Express Scripts Takes It

    $131.00

    Sanofi and Regeneron made an offer: They would drop the cost of their PCSK9 inhibitor Praluent (alirocumab) for improved access. Express Scripts took them up on it. Learn whether this deal will affect the high rejection rate for PCSK9 drugs. Find out whether this deal is a one-off or the start of a trend.

    May 1, 2018
    Find out more

  • GSK’s Head Of Artificial Intelligence Unveils R&D Goals

    $131.00

    In this interview, John Baldoni describes GlaxoSmithKline’s artificial intelligence efforts. Baldoni, who leads GSK’s AI initiative, discusses the company’s machine-driven discovery and development methods and how they can cut time and costs. Gain insights into the AI team’s timeline and what it has accomplished already. Discover who GSK’s AI partners are–and why such deals are “tricky.”

    April 30, 2018
    Find out more
Page 4 of 20
Page 4 of 20«‹23456›»
  • Home
  • Terms and Conditions
  • Refund policy
  • Privacy Policy
  • Cookie Policy
  • Contact Us
  • About Us
  • Discounts
  • Market Spotlight – Reports
  • twitter
  • linkedin
  • Sitemap
Datamonitor Healthcare is part of Pharma intelligence Datamonitor Healthcare is a trading division of Datamonitor Limited, a company registered in England and Wales with company number 2306113 whose registered office is 5 Howick Place, London, SW1P 1WG. VAT GB365462636. Datamonitor Limited is part of Informa PLC.

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC
  • Informa PLC
  • ABOUT US
  • INVESTOR RELATIONS
  • TALENT
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726
informa
Call Back
Scroll to top